Peer-reviewed veterinary case report
Simparica Trio prevents Babesia canis infection from ticks in dogs
By Borowski, Stasia et al.·Published in Parasites & vectors·2024·Zoetis Belgium SA·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of the efficacy of Simparica Trioin the prevention of the transmission of Babesia canis by infected Dermacentor reticulatus to dogs.
- Species:
- dog
Plain-English summary
A group of dogs was tested to see if Simparica Trio could prevent them from getting sick from a tick-borne disease called babesiosis, caused by Babesia canis. The dogs were either given the medication or a placebo, and those that received Simparica Trio showed no signs of illness or positive test results for the disease, while all the dogs that received the placebo did become sick. This means that Simparica Trio was 100% effective in preventing the disease for at least 28 days after treatment. No side effects were noted in any of the dogs treated with the medication.
People also search for: dog tick disease prevention · Simparica Trio for dogs · babesiosis symptoms in dogs
Abstract
BACKGROUND: Babesia canis is a clinically relevant vector-borne pathogen in dogs, and its presence is expanding. The efficacy of Simparica Trio(Zoetis) in the prevention of B. canis transmission was evaluated at the minimum recommended label dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel per kg bodyweight. METHODS: Twenty-four (24) dogs were randomly allocated to either a placebo-treated group or one of two treatment groups with Simparica Trio. Dogs were infested with B. canis-infected Dermacentor reticulatus ticks 21 or 28 days after treatment administration. Blood samples for antibody and DNA detection were collected from each dog prior to tick infestation until 28 days after infestation. A dog was defined as being B. canis positive if it tested positive by both an indirect immunofluorescence assay (IFA) and PCR at any time during the study. RESULTS: No treatment-related adverse reactions were recorded during the study. All placebo-treated animals displayed clinical signs due to babesiosis and tested positive on both IFA and PCR. None of the Simparica Trio-treated animals displayed any clinical symptoms or tested positive, resulting in a 100% efficacy in the prevention of canine babesiosis (P < 0.0001). CONCLUSIONS: A single treatment with Simparica Trio at the minimum recommended label dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel per kg bodyweight prevents the transmission of B. canis by infected D. reticulatus to dogs for at least 28 days.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38308372/